Once again there was a major sell off as the markets grapple with the reality that the vaccine is still a ways off and, meanwhile, there’s a raging pandemic to deal with. All sectors lost, tech and value together, as investors cope with “the reality is that we don’t know what the new normal is going to look like.” The Dow sank 317 with the Nasdaq and S&P also plummeting. The good news is that, despite the day’s drop, the week has been kind with the S&P gaining almost 2 percent this week. (And perhaps the news tonight of Moderna’s promising new treatment was announced after the closing bell; perhaps then a rally tomorrow?) 10.3 billion shares changed hands putting volume on par with the elevated trading that’s been going on the past four weeks.
THU NOVEMBER 12, 2020 6:09 PM
Wall Street ends sharply lower as
pandemic fears resurge
DJ: 29,397.63 -23.29 NAS: 11,786.43 +232.58 S&P: 3,572.66 +27.13 11/11
DJ: 29,080.17 -317.46 NAS: 11,709.59 -76.84 S&P: 3,537.01
-35.65 11/12
(Reuters)
- Wall Street ended sharply lower on Thursday as U.S. coronavirus infections
surged and investors weighed the timeline for the mass rollout of an effective
vaccine. New York became the latest
state to introduce stricter social distancing rules on Wednesday, as new
infections in the country surged above 100,000 for an eighth consecutive day. The blue-chip Dow .DJI was pulled down by
industrial and financial companies sensitive to economic growth, with Boeing
Co BA.N and
Goldman Sachs GS.N down
3% and 1.6%, respectively. Airlines and
cruise operators, among the hardest hit by the coronavirus pandemic, also fell.
The S&P 1500 airlines index .SPCOMAIR dropped
3.1%, while Royal Caribbean Cruises Ltd RCL.N fell 4% and Carnival
Corp CCL.N tumbled
almost 8%.
“The market is reacting to the rise in
COVID cases nationwide,” said Michael Antonelli, a market strategist at Baird
in Milwaukee. “Vaccine
news helps at some point in the future, but today we are dealing with an
accelerating spread,” Even after
Thursday’s drop, the S&P
500 has gained almost 2% this week, buoyed by positive vaccine trial
data that increased expectations of a quick economic recovery. Stocks have also
benefited from expectations that a divided Congress will keep President-elect
Joe Biden from enacting tax hikes that would hurt corporate profits. “The
reality is that we don’t
know what the new normal is going to look like, even when we do recover
from the coronavirus, and that is still a ways away,” said Tom Martin, senior
portfolio manager at Globalt Investments in Atlanta. “It’s the classic between the market
discounting something that is nine to 12 months out, and then ‘undiscounting’
it because it has not happened yet.”
In extended trade, Cisco Systems Inc CSCO.O jumped 8.6% after the network gear maker
reported its quarterly results. New data showed U.S. jobless claims fell
to a seven-month low last week, but the pace of job recovery slowed as fiscal
stimulus waned and further improvement could be limited by a raging pandemic.
The Dow
Jones Industrial Average .DJI fell 1.08% to end at
29,080.17 points, while the S&P 500 .SPX lost 1.00% to
3,537.01. The Nasdaq Composite .IXIC dropped 0.65% to
11,709.59.
Among the biggest boosts to the Nasdaq was a
surge 20% in the U.S.-listed shares of Chinese e-commerce company Pinduoduo
Inc PDD.O after
it reported strong quarterly revenue. Rival JD.com Inc's JD.O shares climbed 4.3%. The S&P 500 energy index .SPNY slumped 4% and
materials .SPLRCM lost
2.5%. Moderna Inc MRNA.O rallied 6.5% after the drugmaker said it
had enough data for a first interim analysis of the late-stage trial of its
experimental COVID-19 vaccine. It did not say when it plans to release the
data.
On U.S. exchanges, 10.3 billion shares changed
hands, compared to an average of 10.0 billion shares for the last 20
sessions.
Declining issues outnumbered advancing
ones on the NYSE by a 2.95-to-1 ratio; on Nasdaq, a 2.17-to-1 ratio favored
decliners. The S&P 500 posted five
new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs
and 11 new lows.
No comments:
Post a Comment